Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

University of Zurich (UZH)

Status: Enrolling

Conditions: HIV Infections

Treatments: Drug: Rilpivirine Injectable Suspension; Biological: Full-length sequencing; Drug: VOCABRIA 30Mg Tablet; Drug: EDURANT 25Mg Tablet; Biological: Intact proviral DNA assay; Drug: Cabotegravir Injectable Suspension

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT06405464

222485 (Other Grant/Funding Number)

903_SHCS

Details and patient eligibility

About

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant in the SHCS
• All SHCS participants initiating the CAB+RPV LA regimen
• All SHCS participants on SOC oral regimen

Exclusion criteria

• Not participating in the SHCS

Trial design

600 participants in 2 patient groups

Swiss HIV Cohort Study participants on CAB+RPV LA regimen

Description:

Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen

Treatment:

Drug: Cabotegravir Injectable Suspension

Biological: Intact proviral DNA assay

Biological: Full-length sequencing

Drug: EDURANT 25Mg Tablet

Drug: VOCABRIA 30Mg Tablet

Drug: Rilpivirine Injectable Suspension

Swiss HIV Cohort Study participants on a standard of care oral regimen

Description:

Matched control population on a standard of care oral regimen

Treatment:

Biological: Intact proviral DNA assay

Biological: Full-length sequencing